According to a Jan. 23 news release, Centene received $660 million in closing costs. The payer will receive $150 million in cash and Evolent common stock in 2024 if certain performance metrics are achieved.
Centene said it planned to sell Magellan Specialty Health to Evolent in November. Centene acquired parent company Magellan Health in January 2022.
In December, Centene sold pharmaceutical benefit manager MagellanRx to Prime Therapeutics.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 17–19 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
